Full Press Release Details
PONTE VEDRA, Fla. , April 11 , 2024 — Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, will present at Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET . The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.
Attendees interested in viewing the live presentation can register for this event, at no cost, here: Virtual Healthcare Equity Conference Registration
Scheduled 1×1 meetings with our management are also available for registered, qualified investor attendees. Please contact your Noble Capital Markets representative or the Cadrenal’s Investor Relations team at CVKD@LythamPartners.com .
A video webcast of the presentation will be available following the event on the Company’s website at https://www.cadrenal.com/investors/ , and as part of a complete catalog of presentations available at on Channelchek , the investor portal created by Noble. The webcast will be archived on the company’s website and on Channelchek.com for 90 days following the event.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib) and just received orphan drug designation for the prevention of thrombosis and thromboembolism in patients with ventricular assist devices (VADs). Cadrenal is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease.For more information, please visit: www.cadrenal.com .
For more information, please contact: